| Followers | 4 |
| Posts | 175 |
| Boards Moderated | 0 |
| Alias Born | 01/08/2022 |
Wednesday, November 19, 2025 2:09:12 PM
SAB - Nice Response. Yes, the details of the process is lacking and without real world experience with the CHMP and baby bio's for that matter I should not have invested in this stock at such an amateur level. But like you I sure have learned a lot over the past 7 years.
Come to think of it, Doc and a few others were the ones that got it right, and others that seem to have great knowledge were incorrect (Mayo included). And I like Mayo and still do.
Another issue for the stock was the 30 % short of the float (~28 Million Shorted). I should have never invested so much knowing that the retail was up against it. I witnessed over and over again the positive PRs from the company and the stock would initially go up and then a Tweet from AF or now Shkreli (Pharma Bros) and the stock would plummet. Apparently completely legal as long as they just preached their opinion 🥴 (free speech). No, whales ever came in to rescue the stock, and probably applauded the Shorts by getting the stock back under 4 so they could buy up those shares.... Lol.
The Shorts still seem to be in control and I agree only a viable partnership announcement could stick it to the Shorts in the near term. The meeting with the FDA to discuss the new data analysis seems plausible, but I assume any fast track still is away out.
I have taken up enough of your time. Hope you and the family are doing well enjoy the holiday season! Wishing you the best.
I will continue to follow to see how this AVXL story ends.
IGB
Come to think of it, Doc and a few others were the ones that got it right, and others that seem to have great knowledge were incorrect (Mayo included). And I like Mayo and still do.
Another issue for the stock was the 30 % short of the float (~28 Million Shorted). I should have never invested so much knowing that the retail was up against it. I witnessed over and over again the positive PRs from the company and the stock would initially go up and then a Tweet from AF or now Shkreli (Pharma Bros) and the stock would plummet. Apparently completely legal as long as they just preached their opinion 🥴 (free speech). No, whales ever came in to rescue the stock, and probably applauded the Shorts by getting the stock back under 4 so they could buy up those shares.... Lol.
The Shorts still seem to be in control and I agree only a viable partnership announcement could stick it to the Shorts in the near term. The meeting with the FDA to discuss the new data analysis seems plausible, but I assume any fast track still is away out.
I have taken up enough of your time. Hope you and the family are doing well enjoy the holiday season! Wishing you the best.
I will continue to follow to see how this AVXL story ends.
IGB
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
